Regeneron Pharmaceuticals Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 40,558,700,000.00 | ROE | 77.07 % |
| Balance Sheet | Total Equity | 31,256,900,000.00 | ROA | 11.11 % |
| Cashflow | Capital Expenditures | -1,213,700,000.00 | P/FCF | 20.72 |
| Cashflow | Free Cash Flow | 4,080,499,968.00 | – | – |
| Cashflow | Operating Cash Flow | 4,978,900,000.00 | P/CF | 16.98 |
| Income | Earnings per Share (diluted) | 41.48 | Div. Yield | 0.45 % |
| Income | Net Income | 4,504,900,000.00 | P/E | 18.76 |
| Income | Shares Outstanding | 108,600,000.00 | P/B | 2.70 |
| Income | Total Revenue | 14,342,900,000.00 | P/S | 5.89 |
Ratios calculated on: 10/14/2026
Company Description
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.regeneron.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more